At the 2013 Annual Meeting for AABB, Quotient presented two posters of the first published results from our development program, MosaiQ™. The first poster, which had been selected by AABB as a "Top Poster" and entitled "Evaluation of a Novel Serology-Based Platform for Irregular Blood Group Antibody Identification (MosaiQ™)", presented data from a 1,000 sample study demonstrating the ability to identify irregular blood group antibodies using MosaiQ™.
The second poster entitled "ABO and Rh Antigen Typinng of Red Blood Cells Using a Novel Serology Based Multiplexed Protein Microarray Platform (MosaiQ™)" presented data from a study using 1,022 samples demonstrated the feasibility of the MosaiQ™ platform as an antigen typing platform.
In both studies results were compared and correlated to column agglutination technology.
There will be several more scientific presentations on MosaiQ™ in the next few months.